NEW YORK (TheStreet) -- RATINGS CHANGES
Watch the video below for more of Friday's analysts' actions:
was initiated with a market perform rating at BMO Capital. Twelve-month price target is $52.
remains a drag on growth, BMO Capital said.
Impax Labs (IPXL) was upgraded at Needham to buy from hold. Twelve-month price target is $37. CorePharma deal can boost earnings, Needham said.
J.C. Penney (JCP) - Get Report was downgraded at Maxim Group to sell from hold. Twelve-month price target is $4. Company is facing increased competition and may struggle to meet sales expectations, Maxim Group said.
Microchip (MCHP) - Get Report was downgraded at Drexel Hamilton to hold from buy. Twelve-month price target is $38. Company is losing market share in the core microcontroller business, Drexel Hamilton said.
Microchip was downgraded at Needham to hold from buy. Company cut sales guidance, as the industry is likely facing an inventory correction, Needham said.
Parexel (PRXL) was downgraded at ISI Group to neutral from buy. Twelve-month price target is $66. Valuation call, as the stock is up 35% year to date, ISI Group said.
Quintiles (Q) was upgraded at ISI Group to buy. Twelve-month price target is $61. Company can deliver better product development growth, ISI Group said.
Regional Management RM was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: RM Ratings Report.
Riverbed (RVBD) was downgraded at Citigroup to neutral from buy. Company guided to lower sales once again, Citi said. Twelve-month price target is $21.
Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.
This article was written by a staff member of TheStreet.